Tarsus Pharmaceuticals, Inc. (TARS)
61.27
-0.28
(-0.45%)
USD |
NASDAQ |
Jun 10, 16:00
61.80
+0.53
(+0.87%)
Pre-Market: 09:08
Tarsus Pharmaceuticals Research and Development Expense (Quarterly) : 22.35M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 22.35M |
| December 31, 2025 | 18.04M |
| September 30, 2025 | 16.28M |
| June 30, 2025 | 15.59M |
| March 31, 2025 | 14.41M |
| December 31, 2024 | 16.87M |
| September 30, 2024 | 12.13M |
| June 30, 2024 | 12.32M |
| March 31, 2024 | 12.07M |
| December 31, 2023 | 13.30M |
| September 30, 2023 | 12.10M |
| June 30, 2023 | 12.55M |
| March 31, 2023 | 12.36M |
| December 31, 2022 | 10.03M |
| Date | Value |
|---|---|
| September 30, 2022 | 10.91M |
| June 30, 2022 | 9.603M |
| March 31, 2022 | 12.08M |
| December 31, 2021 | 8.038M |
| September 30, 2021 | 10.21M |
| June 30, 2021 | 7.204M |
| March 31, 2021 | 16.26M |
| December 31, 2020 | 7.572M |
| September 30, 2020 | 7.991M |
| June 30, 2020 | 1.737M |
| March 31, 2020 | 1.512M |
| December 31, 2019 | 0.697M |
| September 30, 2019 | 0.399M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Structure Therapeutics, Inc. | 66.71M |
| Eton Pharmaceuticals, Inc. | 1.875M |
| Alumis, Inc. | 80.67M |
| Veradermics, Inc. | 20.92M |
| ANI Pharmaceuticals, Inc. | 10.60M |